Holen Sie sich die Stockscreener-App
0.9811
0.00%
0.00
Handel nachbörslich:
.98
-0.0011
-0.11%
Lucid Diagnostics Inc Aktie (LUCD) Neueste Nachrichten
Lucid Diagnostics Inc. (NASDAQ:LUCD) Q2 2025 Earnings Call Transcript - Insider Monkey
PAVmed's EsoGuard Cancer Test Hits 2,756 Q2 Tests as Medicare Coverage Decision Nears - Stock Titan
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results - BioSpace
Lucid Diagnostics Q2 2025 Earnings: Revenue Up, Loss Widens Amid Ongoing Expenses - AInvest
Lucid Diagnostics Reports Q2 2025 Earnings - TipRanks
Lucid Diagnostics Reports Q2 2025 Financial Results - TipRanks
Lucid Diagnostics Maintains Buy Rating Amid Potential Medicare Coverage Expansion and Financial Stability - AInvest
Lucid Diagnostics Reports Q2 Earnings, Revenue Below Consensus, CEO Optimistic on Medicare Coverage - AInvest
Lucid Diagnostics (LUCD): Navigating Medicare Coverage Milestones and Commercial Expansion to Unlock Long-Term Value - AInvest
Lucid Diagnostics Q2 2025: Conflicting Insights on Medicare Coverage, Patient Strategy, and Claims Process - AInvest
Lucid Diagnostics at Canaccord Conference: Medicare Coverage in Focus By Investing.com - Investing.com Canada
Lucid Diagnostics: Needham Reiterates Buy Rating, Raises PT to $3 - AInvest
Transcript : PAVmed Inc., Lucid Diagnostics Inc., Q2 2025 Earnings Call, Aug 13, 2025 - MarketScreener
Earnings call transcript: Lucid Diagnostics highlights Q2 2025 growth and Medicare focus - Investing.com
Lucid Diagnostics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings call transcript: Lucid Diagnostics Q2 2025 revenue up, stock dips - Investing.com UK
Lucid Diagnostics Q2 2025 Earnings: Revenue Exceeds Expectations, EPS Beats Estimates, Cash Position Strengthens - AInvest
Lucid Diagnostics Inc. (LUCD) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Lucid Diagnostics reports $1.2mln revenue, $30mln cash, extends runway past reimbursement milestones. - AInvest
Lucid Diagnostics Inc: Navigating Earnings Challenges and Strategic Growth in a Competitive Diagnostics Landscape - AInvest
Lucid Diagnostics Advances Towards Medicare Coverage - TipRanks
Lucid Diagnostics earnings beat, revenue was in line with estimates By Investing.com - Investing.com Canada
Lucid Diagnostics Inc Q2 loss per share $0.08 - MarketScreener
Lucid Diagnostics Q2 revenue up 1000% YoY to $1.2mln, cash runway extended. - AInvest
LUCD Reports Results - Nasdaq
Lucid Diagnostics 2025 Q2 Earnings Losses Narrow as Net Income Improves 59.7% - AInvest
Lucid Diagnostics Inc. SEC 10-Q Report - TradingView
PAVmed's Q2 2025 Earnings: A Strategic Inflection Point in Healthcare Innovation and Financial Turnaround - AInvest
What To Expect From Lucid Diagnostics Inc (LUCD) Q2 2025 Earnings - Yahoo Finance
Lucid Diagnostics LUCD 2025Q2 Earnings Preview Downside Anticipated on Underwhelming Market Performance - AInvest
Why Lucid Diagnostics Inc. stock attracts strong analyst attentionDaily Growth Stock Pick Reports Show Bullish Signals - metal.it
Lucid Diagnostics to Participate in Upcoming Investor Conferences - Eastern Progress
Cancer Prevention Leader Lucid Diagnostics Headlines Two Major Healthcare Investment Conferences This Month - Stock Titan
Lucid Diagnostics Inc. Breakout Confirmed by Volume MetricsROI Boosting Trade Opportunity Calendar Published - beatles.ru
What institutional investors are buying Lucid Diagnostics Inc. stockFree Trading Strategy Suggestions - Jammu Links News
Does Lucid Diagnostics Inc. stock perform well during market downturnsInvest confidently with actionable market data - Jammu Links News
How strong is Lucid Diagnostics Inc. company’s balance sheetConsistent triple-digit returns - Jammu Links News
What are the technical indicators suggesting about Lucid Diagnostics Inc.Achieve consistent profits with expert advice - Jammu Links News
When is Lucid Diagnostics Inc. stock expected to show significant growthUnlock your portfolio’s full growth potential - Jammu Links News
Is Lucid Diagnostics Inc. a good long term investmentFree Stock Chart Pattern Guide - Jammu Links News
Should I hold or sell Lucid Diagnostics Inc. stock in 2025Outstanding capital growth - Jammu Links News
What are Lucid Diagnostics Inc. company’s key revenue driversRapid capital growth - Jammu Links News
Published on: 2025-08-03 06:14:38 - Jammu Links News
How does Lucid Diagnostics Inc. generate profit in a changing economyMaximize returns with smart investment plans - Jammu Links News
PAVmed gets 180-day extension to regain Nasdaq listing compliance - MSN
PAVmed CEO and CFO to Present Q2 2025 Results and Growth Strategy Update on August 14 - Stock Titan
Lucid Diagnostics to Host Business Update Conference Call and Webcast on August 13, 2025 - AInvest
Lucid Diagnostics Announces Business Update Conference Call on August 13, 2025 - AInvest
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025 - WV News
Lucid nearing Medicare coverage for EsoGuard test, maintain at Buy: BTIG - MSN
What drove LUCD's surprise Q3 earnings beat? - AInvest
What explains LUCD's volatile earnings in 2024? - AInvest
Lucid Diagnostics Awaits Medicare Coverage for EsoGuard Test: Analysts Project 245.48% Price Appreciation and 333.71% Upside Potential - AInvest
Lucid Diagnostics on Track for Medicare Coverage Boosts BTIG's Buy Rating to $2 Target - AInvest
Why did LUCD's Q4 earnings fall short of forecasts? - AInvest
How does Lucid Diagnostics Inc. compare to its industry peersStock Strategy Picks For 2025 - jammulinksnews.com
Lucid Diagnostics' Medicare Coverage Catalyst: A Strategic Inflection Point for Esophageal Cancer Prevention - AInvest
How many analysts rate Lucid Diagnostics Inc. as a “Buy”Achieve consistent profits with expert strategies - Jammu Links News
2.30%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):